ReviewFrontiers in psychiatry2020
Antidepressant Prescribing and Suicide/Self-Harm by Young Australians: Regulatory Warnings, Contradictory Advice, and Long-Term Trends.
Review in Frontiers in psychiatry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 31 citations in OpenAlex.
- New generation antidepressants for depression in children and adolescents: a network meta-analysis.The Cochrane database of systematic reviews · 2021Pooled it
- Interventions for self-harm in children and adolescents.The Cochrane database of systematic reviews · 2021Pooled it
- Persistence of antidepressant treatment in children and adolescents: A population-based cohort study.The Australian and New Zealand journal of psychiatry · 2026Article
- Clinical characteristics and predictive modelling of intentional self-poisoning with prescribed medications among Chinese adolescents: a five-year retrospective study.BMC psychiatry · 2026Article
- Examining drug poisoning in child and adolescent psychiatric patients: clinical analysis and pharmacy services.Frontiers in psychiatry · 2025Article
- Analysis of the traits of deliberate substance abuse and its correlation with psychological states in adolescents.Frontiers in psychiatry · 2025Article
- Country-specific psychopharmacological risk of reporting suicidality comparing 38 antidepressants and lithium from the FDA Adverse Event Reporting System, 2017-2023.Frontiers in psychiatry · 2024Article
- The rise in mortality due to intentional self-poisoning by medicines in Brazil between 2003 and 2022: relationship with regional and global crises.Frontiers in public health · 2024Article
- Growth in emergency department self-harm or suicidal ideation presentations in young people: Comparing trends before and since the COVID-19 first wave in New South Wales, Australia.The Australian and New Zealand journal of psychiatry · 2023Article
- Why psychiatry needs an honest dose of gentle medicine.Frontiers in psychiatry · 2023Review
- Health of children in Australian immigration detention centres: An analysis of the quarterly health reports from 2014 to 2017.Journal of paediatrics and child health · 2022Article
- Can Fluoxetine Combined with Cognitive Behavioral Therapy Reduce the Suicide and Non-Suicidal Self-Injury Incidence and Recurrence Rate in Depressed Adolescents Compared with Fluoxetine Alone? A Meta-Analysis.Neuropsychiatric disease and treatment · 2022Review
- "Drugs to avoid" to improve quality use of medicines: how is Australia faring?Journal of pharmaceutical policy and practice · 2021Article
- From Mental Health Industry to Humane Care. Suggestions for an Alternative Systemic Approach to Distress.International journal of environmental research and public health · 2021Review
- Comorbid Chronic Pain and Depression: Shared Risk Factors and Differential Antidepressant Effectiveness.Frontiers in psychiatry · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In 2004, the US Food and Drug Administration (FDA) controversially issued a black box warning that antidepressants were associated with an increased risk of suicidal thoughts and behaviours in people aged under 18 years. In 2007, the warning was expanded to include young adults aged under 25 years. In 2005, the Australian Therapeutic Goods Administration responded to the FDA warning by requiring Product and Consumer Information leaflets to be updated to reflect the risk. However, there was considerable debate, and at times emotive backlash, in academic journals and the international media. Prominent US and Australian mental health organisations and psychiatrists challenged the FDA warning. They argued that, on balance, antidepressant use was likely to reduce the risk of suicide. Several ecological studies were cited misleadingly as evidence that decreasing antidepressant use increases suicide risk. From 2008 to 2018, Australian per-capita child, adolescent and young adult antidepressant dispensing (0-27 years of age) and suicide (0-24 years) rates have increased approximately 66% and 49%, respectively. In addition, there was a 98% increase in intentional poisonings among 5 to 19 year-olds in New South Wales and Victoria between 2006 and 2016, with substantial overlap between the most commonly dispensed psychotropics and the drugs most commonly used in self-poisoning. These results do not support claims that increased antidepressant use reduces youth suicide risk. They are more consistent with the FDA warning and the hypothesis that antidepressant use increases the risk of suicide and self-harm by young people. Causal relationships cannot be established with certainty until there is a vast improvement in post-marketing surveillance. However, there is clear evidence that more young Australians are taking antidepressants, and more young Australians are killing themselves and self-harming, often by intentionally overdosing on the very substances that are supposed to help them.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.